Antimicrobial resistance in the Russian Federation: ways to solve the problem

Introduction. Antimicrobial resistance is one of the leading threats to public health and to the sustainability of healthcare systems, and its containment has been designated a national priority of the Russian Federation. The purpose of the study: to systematize modern ideas about the scale and driving factors of antimicrobial resistance in the Russian Federation and to justify the transition from a list of disparate measures to an integrated model of its containment. Materials and methods. The analytical review is based on domestic and foreign publications for 2017–2025, regulatory legal acts and data from the national multicenter sustainability monitoring. The sources were searched in the repositories PubMed, CyberLeninka, eLibrary.RU, as well as through the Google search engine. Logical, comparative, structural methods and content analysis were used to study the generated array of relevant publications. Results. According to the data obtained, there is a tendency to increase the resistance of pathogens, mainly gram-negative ones, in hospital settings. At the same time, the key limitation remains not the lack of scientific knowledge, but the gap between evidence-based approaches and their actual implementation in practice, which is mainly behavioral and organizational in nature. National surveillance information infrastructure and specific vaccine prevention are considered as underestimated, but complementary points of application that can reduce the need for antimicrobials and limit the selection of resistant strains. Conclusion. Antimicrobial resistance cannot be contained by a single instrument; a sustainable outcome is provided by a systemic loop combining resistance monitoring, rational pharmacotherapy, vaccination and a managed digital environment for their implementation, individual elements of which are already being created in the Russian Federation and require organisational and informational integration.

1. Naghavi M., Vollset S. E., Ikuta K. S. et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet. 2024; 404 (10459): 1199–1226. DOI: 10.1016/S0140-6736(24)01867-1.

2. . Murray C.J.L., Ikuta K. S., Sharara F. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022; 399(10325):629–655. DOI: 10.1016/S0140-6736(21)02724-0.

3. Sati H., Carrara E., Savoldi A. et al . The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. The Lancet Infectious Diseases. 2025; 25(9):1033–1043. DOI: 10.1016/S14733099(25)00118-5.

4. Global Action Plan on Antimicrobial Resistance. Geneva: WHO; 2015. p. 28.

5. Decree of the Government of the Russian Federation dated September 25, 2017 No. 2045-r «On the Strategy for preventing the spread of antimicrobial resistance in the Russian Federation for the period up to 2030.» Available from: http://static.government.ru/media/files/onJ3GY3ObDGqLDvrED7AhpLF3ywRRFpp.pdf (Date accessed: April 27, 2026). (In Russ.).

6. Sukhorukova M.V., Edelstein M. V., Ivanchik N. V. et al. Antimicrobial resistance of nosocomial Enterobacterales isolates in Russia: results of the multicentre epidemiological study MARATHON2015–2016. Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(2):147–159. DOI: 10.36488/cmac.2019.2.147–159. (In Russ.).

7. MARATHON Study Group. Antimicrobial resistance of nosocomial Enterobacteriaceae isolates in Russia: results of the national multicentre surveillance study MARATHON2011–2012. Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(4):254–265. (In Russ.).

8. Sukhorukova M.V., Edelstein M. V., Skleenova E.Yu. et al. Antimicrobial resistance of nosocomial Enterobacteriaceae isolates in Russia: results of the multicentre epidemiological study MARATHON2013–2014. Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(1):49–56. (In Russ.).

9. Shajdullina E.R., Edelstein M. V., Skleenova E. Yu., Sukhorukova M. V., Kozlov R. S. Antimicrobial resistance of nosocomial carbapenemase-producing Enterobacterales in Russia: results of surveillance, 2014–2016. Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(4):362–369. (In Russ.).

10. Pokida A.N., Zybunovskaya N. V . Self-medication practices of the Russian population in modern conditions. Public Health and Life Environment (ZNiSO). 2023; 31(2):15–26. DOI: 10.35627/2219–5238/2023-31-2-15-26. (In Russ.).

11. Verlan N.V., Moroz T. L., Kochkina E. O., Bochanova E. N., Beygel E. A . Analysis of data on adverse reactions during antibiotic self-medication and on pharmacovigilance system functioning. Safety and Risk of Pharmacotherapy. 2022; 10(3):240–250. DOI: 10.30895/2312-7821-2022-10-3-240-250. (In Russ.).

12. Zaytsev A.A., Makarevich A. M . Antimicrobial therapy and COVID-19 the great confrontation. Antibiotics and Chemotherapy. 2022; 67(9–10):63–68. (In Russ.).

13. Ginzburg A.S., Kiryutkina A. P., Migacheva N. B . Use of antibacterial drugs in the treatment of coronavirus infection in children in real outpatient practice. Allergology and Immunology in Pediatrics. 2023; (2):6–15. (In Russ.).

14. Kuzmenkov A.Y., Trushin I. V., Vinogradova A. G. et al. AMRmap: an interactive web platform for analysis of antimicrobial resistance surveillance data in Russia. Frontiers in Microbiology. 2021; 12:620002. DOI: 10.3389/fmicb.2021.620002.

15. Kuzmenkov A.Y., Vinogradova A. G., Trushin I. V. et al. AMRmap antibiotic resistance surveillance system in Russia. Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(2):198–204. DOI: 10.36488/cmac.2021.2.198204. (In Russ.).

16. Stoma I. O . Vaccination as a strategy to overcome antimicrobial resistance: a fresh look at a known problem. Journal Infectology. 2023; 15(1):5–15. DOI: 10.22625/2072-6732-2023-15-1-5-15. (In Russ.).

17. Estimating the impact of vaccines in reducing antimicrobial resistance and antibiotic use. Geneva: WHO; 2024. p. 168.

18. von Gottberg A., de Gouveia L., Tempia S. et al. Effects of vaccination on invasive pneumococcal disease in South Africa. New England Journal of Medicine. 2014; 371(20):1889–1899. DOI: 10.1056/NEJMoa1401914.

19. Brueggemann A.B., van Rensburg M. J.J., Shaw D. et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic. The Lancet Digital Health. 2021; 3(6): e360–e370. DOI: 10.1016/S2589-7500(21)00077-7.

20. Muravyev A.A., Chagaryan A. N., Ivanchik N. V. et al. The prevalence of circulating Streptococcus pneumoniae serotypes in people older than 18 years: healthy carriers, patients with acute otitis media, community-acquired pneumonia, and invasive pneumococcal infections (epidemiological study SPECTRUM). Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(4):275–281. (In Russ.).

21. Bykonya S.A. et al. The prevalence and antimicrobial susceptibility of circulating Streptococcus pneumoniae serotypes in the adult population in Russia (epidemiological study SPECTRUM). Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(2):127–137. (In Russ.).

22. Muravyev A.A., Chagaryan A. N., Ivanchik N. V. et al . Epidemiological characteristic of Streptococcus pneumoniae serotypes from patients with invasive pneumococcal disease in the Russian Federation. Clinical Microbiology and Antimicrobial Chemotherapy. 2025; 27(2):134–139. (In Russ.).